Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYDRO-PROTECT
NL-OMON60477Phase 3Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Hydrochlorothiazide add-on with Placebo add-on (2 arms). Primary endpoint: Rate of kidney function decline. Started Jun 2024; status: recruiting.
02
Drugs
hydrochlorothiazide
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NL-OMON60477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60477.